News Search
|
All News Topics
>
Companies
;
Press Releases by Industry Channel
>
All Companies Press Releases
Amarantus BioSciences to Present at the Wall Street 1-2-1 Conference AMBS(OTC.BB)
/EINPresswire.com/ SUNNYVALE, CA- May 9, 2012 - Amarantus BioSciences, Inc. (OTCBB: AMBS), a biotechnology company developing Mesencephalic-Astrocyte-derived Neurotrophic Factor (MANF) for the treatment of Parkinson's disease and other nervous system disorders, today announced that it has been selected to participate in the Wall Street 1-2-1 Conference in Orlando, Florida at the Rosen Shingle Creek Resort May 8-11, 2011. Mr. Gerald Commissiong, Amarantus' President & CEO, will be a featured presenter at this event. Topics will include development of the MANF Program, business development activities, and strategy for growth.
The Wall Street 1-2-1 Event is an innovative approach to bringing together - in one place at one time - 100 of the nation's leading professional investment firms with the corporate executives from up to 125 high growth public and pre-public companies to achieve their respective investment screening and market exposure objectives. The event features a series of four "Meet the Money" sessions over a fast-paced two-day period in which executive management teams of each participating company will present their business overview, catalysts for growth, and investment opportunity to each of the 100 investment firms in attendance. Wall Street 1-2-1 will welcome over 500 attendees to its Spring Event in Orlando, Florida on May 8-12, 2012. For more information, or to register for the event, visit www.wallstreet121.com
EVENT INFORMATION AT A GLANCE:
WHO: Gerald Commissiong, President and Chief Executive Officer
WHEN: May 8th through May 11th, 2012
WHERE: Rosen Shingle Creek Resort, located at 9939 Universal Blvd Orlando, Florida 32819
WEBSITE: http://www.wallstreet121.com
About MANF (Mesencephalic-Astrocyte-derived Neurotrophic Factor)
MANF (Mesencephalic-Astrocyte-derived Neurotrophic Factor) is a protein that corrects protein misfolding, one of the major causes of apoptosis (cell death). This property provides a compelling rationale for the research and development of MANF-based products as therapeutics for human disease. The lead MANF product development effort is centered on a therapy for Parkinson's disease, currently funded by a research grant from the Michael J. Fox Foundation for Parkinson's Research and a secondary program funded by the Brewer Sports International developing new treatments for Traumatic Brain Injury. The Company also owns an inventory of 88 cell lines referred to as "PhenoGuard Cell Lines." MANF was the first therapeutic protein discovered from a PhenoGuard Cell Line. It is anticipated that additional therapeutic proteins useful for various therapeutic approaches to the Central Nervous System (CNS) will be identified from the Company's inventory of PhenoGuard Cell Lines.
About Amarantus BioSciences, Inc.
Amarantus BioSciences, Inc. is a development-stage biotechnology company founded in January 2008. The Company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat Parkinson's disease, Traumatic Brain Injury and other human diseases. The Company owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for human disorders. For further information please visit http://www.Amarantus.com .
Seraphim Strategies
Lou Levenstein
727.489.9939
www.tomorrowsbluechips.com
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the possible benefits of MANF therapeutic applications and/or advantages presented by Amarantus' PhenoGuard technology, as well as statements about expectations, plans and prospects of the development of Amarantus' new product candidates. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including the risks that the anticipated benefits of the therapeutic drug candidates or discovery platforms, as well as the risks, uncertainties and assumptions relating to the development of Amarantus' new product candidates, including those identified under "Risk Factors" in Amarantus' most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q and in other filings Amarantus periodically makes with the SEC. Actual results may differ materially from those contemplated by these forward-looking statements Amarantus does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this presentation.
The Wall Street 1-2-1 Event is an innovative approach to bringing together - in one place at one time - 100 of the nation's leading professional investment firms with the corporate executives from up to 125 high growth public and pre-public companies to achieve their respective investment screening and market exposure objectives. The event features a series of four "Meet the Money" sessions over a fast-paced two-day period in which executive management teams of each participating company will present their business overview, catalysts for growth, and investment opportunity to each of the 100 investment firms in attendance. Wall Street 1-2-1 will welcome over 500 attendees to its Spring Event in Orlando, Florida on May 8-12, 2012. For more information, or to register for the event, visit www.wallstreet121.com
EVENT INFORMATION AT A GLANCE:
WHO: Gerald Commissiong, President and Chief Executive Officer
WHEN: May 8th through May 11th, 2012
WHERE: Rosen Shingle Creek Resort, located at 9939 Universal Blvd Orlando, Florida 32819
WEBSITE: http://www.wallstreet121.com
About MANF (Mesencephalic-Astrocyte-derived Neurotrophic Factor)
MANF (Mesencephalic-Astrocyte-derived Neurotrophic Factor) is a protein that corrects protein misfolding, one of the major causes of apoptosis (cell death). This property provides a compelling rationale for the research and development of MANF-based products as therapeutics for human disease. The lead MANF product development effort is centered on a therapy for Parkinson's disease, currently funded by a research grant from the Michael J. Fox Foundation for Parkinson's Research and a secondary program funded by the Brewer Sports International developing new treatments for Traumatic Brain Injury. The Company also owns an inventory of 88 cell lines referred to as "PhenoGuard Cell Lines." MANF was the first therapeutic protein discovered from a PhenoGuard Cell Line. It is anticipated that additional therapeutic proteins useful for various therapeutic approaches to the Central Nervous System (CNS) will be identified from the Company's inventory of PhenoGuard Cell Lines.
About Amarantus BioSciences, Inc.
Amarantus BioSciences, Inc. is a development-stage biotechnology company founded in January 2008. The Company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat Parkinson's disease, Traumatic Brain Injury and other human diseases. The Company owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for human disorders. For further information please visit http://www.Amarantus.com .
Seraphim Strategies
Lou Levenstein
727.489.9939
www.tomorrowsbluechips.com
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the possible benefits of MANF therapeutic applications and/or advantages presented by Amarantus' PhenoGuard technology, as well as statements about expectations, plans and prospects of the development of Amarantus' new product candidates. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including the risks that the anticipated benefits of the therapeutic drug candidates or discovery platforms, as well as the risks, uncertainties and assumptions relating to the development of Amarantus' new product candidates, including those identified under "Risk Factors" in Amarantus' most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q and in other filings Amarantus periodically makes with the SEC. Actual results may differ materially from those contemplated by these forward-looking statements Amarantus does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this presentation.
Powered by
EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.
